KAS
ATXI

Kestra Advisory Services’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Kestra Advisory Services’s Portfolio ATXI Stock Details ATXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-20
Closed -$34K – 2212
2021
Q3 		$34K Buy
+20
New +$41.3K ﹤0.01% 2094

Other funds holding ATXI

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EL
EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return

Kestra Advisory Services's ATXI Position: Q4 2021 in Review

Kestra Advisory Services sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q4 2021, closing a stake of 20 shares — an estimated $34K sold.

Kestra Advisory Services first reported a position in ATXI in Q3 2021 and held it in 1 quarter. The position peaked at $34K in Q3 2021. 14 funds tracked by Wall St. Rank hold ATXI as of Q4 2021.

  • Kestra Advisory Services reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Kestra Advisory Services sold 20 Avenue Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $34K.
  • Kestra Advisory Services first reported a position in Avenue Therapeutics, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Kestra Advisory Services's Avenue Therapeutics, Inc. Common Stock position peaked at $34K in Q3 2021.
  • 14 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Kestra Advisory Services's 13F filing for Q4 2021, filed 20 Jan 2022.